InVivoSIM anti-human TIGIT (Tiragolumab Biosimilar)

About InVivoSIM anti-human TIGIT (Tiragolumab Biosimilar)

This non-therapeutic biosimilar antibody uses the same variable regions from the therapeutic antibody Tiragolumab making it ideal for research use. The Tiragolumab biosimilar antibody reacts with human TIGIT (T cell immunoreceptor with Ig and ITIM domains). TIGIT is a 26 kDa, type I transmembrane protein and a member of the poliovirus receptor (PVR) family. TIGIT has been found to be expressed on follicular T helper cells in mice while in humans it’s expressed by many T cell subsets including activated T cells, follicular T helper cells, memory T cells, and regulatory T cells as well as on NK cells. TIGIT can interact with certain members of the PVR and PVR-like families, including PVR, PVRL2, PVRL3, CD155, and CD112. TIGIT is thought to negatively regulate NK and T cell activation. Binding of TIGIT on T cells by dendritic cells results in their differentiation into a tolerogenic phenotype, with increased secretion of IL-10 and diminished production of IL-12. TIGIT knock-out mice are more susceptible to autoimmune disease. Tiragolumab binds to TIGIT expressed on tumor-infiltrating T cells thereby preventing the interaction of TIGIT with its ligands CD112 and CD155. This enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 which is expressed on NK cells and CD8+ T cells, and leads to CD226 dimerization and CD226-mediated signaling. This activates the immune system to exert a T-cell-mediated immune response against cancer cells. Tiragolumab, alone or in combination with a PD-L1 inhibitor is used to treat solid malignancies-most notably non-small cell lung cancer (NSCLC).